Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea
The controlled attenuation parameter (CAP) is a noninvasive method of assessing hepatic steatosis. We defined the normal range of CAP values in healthy subjects and evaluated the associated factors.
CAP values were measured in a cohort of healthy subjects who were screened as living liver transplantation donors and those who underwent health checkups. Subjects with current or a history of chronic liver disease, abnormalities on liver-related laboratory tests, or fatty liver on ultrasonography or biopsy were excluded.
The mean age of the 264 recruited subjects (131 males and 133 females; 76 potential liver donors and 188 subjects who had undergone health checkups) was 49.2 years. The mean CAP value was 224.8 ± 38.7 dB/m (range 100.0–308.0 dB/m), and the range of normal CAP values (5th–95th percentiles) was 156.0–287.8 dB/m. The mean CAP value was significantly higher in the health checkup than in the potential liver donor group (227.5 ± 42.0 vs. 218.2 ± 28.3 dB/m, P = 0.040). CAP values did not differ significantly according to gender or age in either group (all P > 0.05). In a multivariate linear regression analysis, body mass index (β = 0.271, P = 0.024) and triglyceride levels (β = 0.348, P = 0.008) were found to be independently associated with CAP values.
We determined the normal range of CAP values and found that body mass index and triglyceride levels were associated with the CAP values of healthy subjects.
KeywordsControlled attenuation parameter Fatty liver Healthy subject Liver donor Normal value
Controlled attenuation parameter
Non-alcoholic fatty liver disease
Liver stiffness value
Chronic liver disease
Body mass index
Hepatitis B virus surface antigen
Hepatitis C virus antibody
Gamma glutamyl transpeptidase
Conflict of interest
- 9.Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.PubMedCrossRefGoogle Scholar
- 11.Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2014. (Epub ahead of print). doi: 10.1111/jgh.12557.
- 16.Contos MJ, Choudhury J, Mills AS et al. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:481–500, vii.Google Scholar
- 27.Carvalhana S, Leitao J, Alves AC, et al. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int. 2013. (Epub ahead of print). doi: 10.1111/liv.12305.
- 32.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.Google Scholar